Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/181797
Title: | Impact of an enhanced screening program on the detection of non-AIDS neoplasias in patients with human immunodeficiency virus infection |
Author: | Masiá, M. Padilla, S. Estañ, G. Portu, J. Silva, A. Rivero, A. González Cordón, Ana García Fraile, L. Martínez, O. Bernal, E. Galera, C. Boix Martínez, Vicente Macias, J. Montero, M. García Rosado, Dácil Vivancos Gallego, M. J. Llenas García, J. Torralba, M. García, J. A. Agulló, V. González Fernández, M. Gutiérrez, F. Martínez, E. IMPAC-NEO Study Group |
Keywords: | Càncer Infeccions per VIH Cribratge Assaigs clínics Cancer HIV infections Medical screening Clinical trials |
Issue Date: | 27-Nov-2021 |
Publisher: | Springer Science and Business Media LLC |
Abstract: | Background: The incidence of non-AIDS defining cancer (NADC) is higher in people living with HIV (PLWH) than in the general population, and it is already one of the leading causes of death in the HIV-infected population. It is estimated that the situation will be aggravated by the progressive aging of PLWH. Early diagnosis through intensive cancer screening may improve the ability for therapeutic interventions and could be critical in reducing mortality, but it might also increase expenditure and harms associated with adverse events. The aim of this study is to evaluate an enhanced screening program for early diagnosis of cancer in PLWH compared to standard practice. The specific objectives are (1) to compare the frequency of cancer diagnosed at an early stage, (2) to analyze safety of the enhanced program: adverse events and unnecessary interventions, (3) to analyze the cost-utility of the program, and (4) to estimate the overall and site-specific incidence of NADC in PLWH. Methods: We will conduct a multicenter, non-blinded, randomized, controlled trial, comparing two parallel arms: conventional vs enhanced screening. Data will be recorded in an electronic data collection notebook. Conventional intervention group will follow the standard of care screening in the participating centers, according to the European AIDS Clinical Society recommendations, and the enhanced intervention group will follow an expanded screening aimed to early detection of lung, liver, anal, cervical, breast, prostate, colorectal, and skin cancer. The trial will be conducted within the framework of the Spanish AIDS Research Network Cohort (CoRIS). Discussion: The trial will evaluate the efficacy, safety, and efficiency of an enhanced screening program for the early diagnosis of cancer in HIV patients compared to standard of care practice. The information provided will be relevant since there are currently no studies on expanded cancer screening strategies in patients with HIV, and available data estimating cost effectiveness or cost-utility of such as programs are scarce. An enhanced program for NADC screening in patients with HIV could lead to early diagnosis and improve the prognosis of these patients, with an acceptable rate of unnecessary interventions, but it is critical to demonstrate that the benefits clearly outweigh the harms, before the strategy could be implemented. |
Note: | Reproducció del document publicat a: https://doi.org/10.1186/s13063-021-05777-6 |
It is part of: | Trials, 2021, vol. 22, num. 1, p. 851 |
URI: | http://hdl.handle.net/2445/181797 |
Related resource: | https://doi.org/10.1186/s13063-021-05777-6 https://doi.org/10.1186/s13063-023-07655-9 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
s13063-021-05777-6.pdf | 875.9 kB | Adobe PDF | View/Open | |
s13063-021-05777-6_CORR.pdf | Correction | 619.36 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License